Literature DB >> 24370612

Analysis of rocuronium in human plasma by liquid chromatography-tandem mass spectrometry with application in clinical pharmacokinetics.

Natália Valadares de Moraes1, Gabriela Rocha Lauretti2, Gabriela Campos de Oliveira Filgueira3, Bruno Carvalho Portes Lopes2, Vera Lucia Lanchote4.   

Abstract

Rocuronium (ROC) is a neuromuscular blocking agent used in surgical procedures which is eliminated primarily by biliary excretion. A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for analysis of ROC in human plasma. Separation of ROC and IS (verapamil) was performed using an endcapped C-18 column and a mixture of water:acetonitrile:trifluoracetic acid (50:50:0.1, v/v) as mobile phase. Aliquots of 100 μL of human plasma were extracted at pH 3, using dichloromethane. The lower limit of quantification of 5 ng/mL shows the high sensitivity of this method. Intra- and inter-assay precision (as relative standard deviation) was all ≤14.2% and accuracy (as relative standard error) did not exceed 10.1%. The validated method was successfully applied to quantify ROC concentrations in patients under surgical procedures up to 6h after the administration of the 0.4-0.9 mg/kg ROC. The pharmacokinetic parameter estimations of ROC showed AUC/dose of 563 μg min/mL, total clearance of 2.5 mL/min/kg, volume of distribution at steady state of 190 mL/kg and mean residence time of 83 min.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Human plasma; LC–MS/MS; Pharmacokinetics; Rocuronium

Mesh:

Substances:

Year:  2013        PMID: 24370612     DOI: 10.1016/j.jpba.2013.11.032

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  2 in total

1.  Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia.

Authors:  Takahiro Moriyama; Akira Matsunaga; Osamu Nagata; Kei Enohata; Tomomi Kamikawaji; Erika Uchino; Yuichi Kanmura
Journal:  J Anesth       Date:  2015-03-01       Impact factor: 2.078

2.  The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries.

Authors:  A C C Costa; E B Coelho; V L Lanchote; B V Correia; J T Abumansur; G R Lauretti; N V de Moraes
Journal:  Eur J Clin Pharmacol       Date:  2017-04-14       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.